Transcatheter arterial infusion chemotherapy with a fine-powder formulation of XXXX for advanced @entity157 refractory to transcatheter arterial chemoembolization.

@entity1 @entity137 @entity882 @entity5 @entity900 @entity492 @entity74 @entity157
OBJECTIVE: The aim of this study was to assess the safety and efficacy of transcatheter arterial infusion chemotherapy using a fine-powder formulation of @entity900 for @entity1 with advanced @entity157 refractory to transcatheter arterial chemoembolization. METHODS: We retrospectively examined the data of 84 consecutive @entity1 with transcatheter arterial @entity157 who underwent transcatheter arterial infusion chemotherapy with a fine-powder formulation of @entity900 . @entity900 was administered at the dose of 65 mg/m(2) into the feeding @entity157 . The treatment was repeated every 4-6 weeks, until the appearance of evidence of @entity5 progression or of unacceptable @entity137 . RESULTS: Of the 84 @entity1 , one @entity1 (1.2%) showed complete response and two @entity1 (2.4%) showed partial response, representing an overall response rate of 3.6% (95% confidence interval, 0.7-10.1). Of the remaining, 38 @entity1 (45.2%) showed stable disease and 41 (48.8%) showed @entity74 . The median overall survival, 1-year survival rate and median progression-free survival in the entire subject population were 7.1 months, 27% and 1.7 months, respectively. Major Grade 3 or 4 adverse events included @entity882 in 12 @entity1 (14%) and elevation of the serum @entity492 aminotransferase in 33 @entity1 (39%). The gastrointestinal @entity137 were mild and reversible. CONCLUSIONS: Transcatheter arterial infusion chemotherapy using a fine-powder formulation of @entity900 appears to have only modest activity, although the @entity137 was also only mild, in @entity1 with transcatheter arterial @entity157 .
